GlassScriptPhysician profile
Lloyd A Costello
NPI 1922059831
$2,854.68
in general payments reported to CMS, 2019-2025
32 companies · $19.98 in 2025
The $19.98 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,846 · 2020: $322 · 2021: $565 · 2022: $68.38 · 2023: $32.81 · 2025: $19.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $52.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $52.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $370.39 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $274.31 | 2021-2022 | |
| Daiichi Sankyo INC. | $257.71 | 2019 | |
| Sanofi-Aventis U.S. LLC | $238.49 | 2019-2021 | |
| Abbvie INC. | $229.65 | 2019 | |
| Collegium Pharmaceutical, INC. | $215.74 | 2019-2020 | |
| Amarin Pharma, INC. | $149.67 | 2020-2023 | |
| Pfizer INC. | $148.92 | 2019-2020 | |
| Vertiflex, INC. | $124.54 | 2019 | |
| Lilly USA, LLC | $94.71 | 2019-2020 | |
| Fidia Pharma USA INC. | $83.67 | 2019 | |
| Novo Nordisk INC | $68.20 | 2021 | |
| Antares Pharma, INC. | $68.17 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $48.61 | 2019 | |
| Kaleo, INC. | $47.47 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.76 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $43.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.66 | 2019-2020 | |
| Sk Life Science, INC. | $37.55 | 2021 | |
| Arbor Pharmaceuticals, INC. | $34.68 | 2020 | |
| Biogen, INC. | $24.58 | 2021 | |
| Scilex Pharmaceuticals INC. | $23.76 | 2019 | |
| Astellas Pharma US INC | $22.90 | 2019 | |
| Mimedx Group, INC. | $19.98 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.69 | 2019 | |
| Sunovion Pharmaceuticals INC. | $18.90 | 2021 | |
| Sentynl Therapeutics, INC. | $18.46 | 2019 | |
| Ucb, INC. | $17.21 | 2021 | |
| Amgen INC. | $16.93 | 2021 | |
| Allergan, INC. | $16.75 | 2020 | |
| Assertio Therapeutics, INC. | $15.97 | 2019 | |
| Boston Scientific Corporation | $15.57 | 2023 | Superion Indirect Decompression System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Costello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.